Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer

Design and development of 99mTc labeled FAPI-tracers for SPECT-imaging and 188Re therapy.

(2020) Thomas Lindner et al.   JOURNAL OF NUCLEAR MEDICINE

Review on 99mTc radiopharmaceuticals with emphasis on new advancements

(2020) Adriano Duatti   NUCLEAR MEDICINE AND BIOLOGY

Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation

(2020) Jessica Bridoux et al.   Biomolecules

Clinical Translation of [68Ga]Ga-NOTA-anti-MMR-sdAb for PET/CT Imaging of Protumorigenic Macrophages

(2019) Catarina Xavier et al.   MOLECULAR IMAGING AND BIOLOGY

Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer

(2019) Yan Xing et al.   JOURNAL OF NUCLEAR MEDICINE

Breast Cancer Treatment

(2019) Adrienne G. Waks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Nanobody: outstanding features for diagnostic and therapeutic applications

(2019) J.-Pablo Salvador et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior

(2019) Yana Dekempeneer et al.   MOLECULAR PHARMACEUTICS

HER2-targeted therapies — a role beyond breast cancer

(2019) Do-Youn Oh et al.   Nature Reviews Clinical Oncology

Breast cancer

(2019) Nadia Harbeck et al.   Nature Reviews Disease Primers

Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity

(2019) Tyler Risom et al.   JOURNAL OF CLINICAL INVESTIGATION

Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations

(2019) Indrė Januškevičienė et al.   LIFE SCIENCES

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2-positive breast cancer: Current and new therapeutic strategies

(2018) Santiago Escrivá-de-Romaní et al.   BREAST

68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study

(2018) Mikhail Kesler et al.   JOURNAL OF NUCLEAR MEDICINE

Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer

(2018) Marek Pruszynski et al.   MOLECULAR PHARMACEUTICS

89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up

(2018) Frederike Bensch et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Risk Factors and Preventions of Breast Cancer

(2017) Yi-Sheng Sun et al.   International Journal of Biological Sciences

First-in-Human Human Epidermal Growth Factor Receptor 2–Targeted Imaging Using89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer

(2017) Gary A. Ulaner et al.   JOURNAL OF NUCLEAR MEDICINE

Breast cancer

(2017) Nadia Harbeck et al.   LANCET

HER2-positive breast cancer

(2017) Sibylle Loibl et al.   LANCET

Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years

(2017) Berit M Pfitzner et al.   MODERN PATHOLOGY

Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation

(2017) Zhengyuan Zhou et al.   MOLECULAR IMAGING AND BIOLOGY

Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review

(2016) C. Yeung et al.   CANCER AND METASTASIS REVIEWS

Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET

(2016) G. Vaidyanathan et al.   JOURNAL OF NUCLEAR MEDICINE

Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab′)2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT

(2016) Karen Lam et al.   mAbs

[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

(2016) Richard Laforest et al.   MOLECULAR IMAGING AND BIOLOGY

18F-nanobody for PET imaging of HER2 overexpressing tumors

(2016) Catarina Xavier et al.   NUCLEAR MEDICINE AND BIOLOGY

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

(2015) G. Gebhart et al.   ANNALS OF ONCOLOGY

Clinical implications of the intrinsic molecular subtypes of breast cancer

(2015) Aleix Prat et al.   BREAST

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

(2015) M. Keyaerts et al.   JOURNAL OF NUCLEAR MEDICINE

Patient dosimetry in nuclear medicine

(2015) Sören Mattsson   RADIATION PROTECTION DOSIMETRY

Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments

(2015) Daniel G. Stover et al.   Current Oncology Reports

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule

(2014) J. Sorensen et al.   JOURNAL OF NUCLEAR MEDICINE

Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody

(2014) Matthias D'Huyvetter et al.   Theranostics

Nanobody: The “Magic Bullet” for Molecular Imaging?

(2014) Rubel Chakravarty et al.   Theranostics

A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases

(2013) Gaetano Aurilio et al.   EUROPEAN JOURNAL OF CANCER

Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer

(2013) C. Xavier et al.   JOURNAL OF NUCLEAR MEDICINE

Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer

(2011) Ilse Vaneycken et al.   FASEB JOURNAL

EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry

(2010) Cecilia Hindorf et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules

(2010) R. P. Baum et al.   JOURNAL OF NUCLEAR MEDICINE

Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

(2009) Kathryn A. Phillips et al.   CANCER